Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

European Journal of Cancer

Volumn 60, Issue , 2016, Pages 190-209

  Hofmann, Lars ^a   Forschner, Andrea ^b   Loquai, Carmen ^c   Goldinger, Simone M ^d   Zimmer, Lisa ^e   Ugurel, Selma ^e   Schmidgen, Maria I ^c   Gutzmer, Ralf ^f   Utikal, Jochen S ^g,h   Göppner, Daniela ⁱ   Hassel, Jessica C ^j   Meier, Friedegund ^k   Tietze, Julia K ^l   Thomas, Ioannis ^b   Weishaupt, Carsten ^m   Leverkus, Martin ⁿ   Wahl, Renate ⁿ   Dietrich, Ursula ^k   Garbe, Claus ^b   Kirchberger, Michael C ^a   Eigentler, Thomas ^b   Berking, Carola ^l   Gesierich, Anja ^o   Krackhardt, Angela M ^p   Schadendorf, Dirk ^e   Schuler, Gerold ^a   Dummer, Reinhard ^d   Heinzerling, Lucie M ^a   more..

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^j UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^k UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^l UNIVERSITY OF MUNICH   (Germany)

^m UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁿ UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^o UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^p TECHNICAL UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

Adverse event; Anti PD 1; Checkpoint inhibitors; Immune related; Nivolumab; Pembrolizumab; Side effect; Tolerability; Toxicity

Indexed keywords

ANALGESIC AGENT; ANTIINFECTIVE AGENT; CARBOPLATIN; CORTICOSTEROID DERIVATIVE; DAPAGLIFLOZIN; DEXAMETHASONE; ENALAPRIL; GLIMEPIRIDE; GLUCOSE; HYDROCORTISONE; INDAPAMIDE; INFLIXIMAB; INSULIN; IPILIMUMAB; LEVOCETIRIZINE; METFORMIN; METHYLPREDNISOLONE; METRONIDAZOLE; MYCOPHENOLATE MOFETIL; MYDRIATIC AGENT; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PREDNISOLONE; SALICYLIC ACID; TRIAMCINOLONE ACETONIDE; UREA; VEMURAFENIB; VITAMIN D DERIVATIVE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ADULT; AGED; ALOPECIA; ANOREXIA; APPETITE DISORDER; ARTICLE; AUTOIMMUNE HEPATITIS; BALANITIS; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; COLITIS; CONTACT ALLERGY; CORTICOSTEROID THERAPY; DERMATITIS; DIARRHEA; ENDOCRINE DISEASE; ESOPHAGITIS; FACE ERYTHEMA; FATIGUE; FECES IMPACTION; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GERMANY; GLUCOSE BLOOD LEVEL; HAIR LOSS; HASHIMOTO DISEASE; HEPATITIS; HEPATOMEGALY; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPOPHYSITIS; HYPOTHYROIDISM; INSULIN DEPENDENT DIABETES MELLITUS; IRITIS; KETOACIDOSIS; KIDNEY DISEASE; KIDNEY FAILURE; LICHEN PLANUS; LIVER BIOPSY; LIVER DISEASE; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL PRURITUS; PANCREAS INSUFFICIENCY; PANCREATITIS; PAPULE; PHOTOPHOBIA; PNEUMONIA; POLYDIPSIA; PRIORITY JOURNAL; PSORIASIS VULGARIS; RETROSPECTIVE STUDY; ROSACEA; SHIVERING; SKIN DEFECT; SKIN DISEASE; SWITZERLAND; SYSTEMIC THERAPY; VERY ELDERLY; VITILIGO; VOMITING; WEAKNESS; WEIGHT REDUCTION; XEROSTOMIA; ANTAGONISTS AND INHIBITORS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ERUPTIONS; MELANOMA; MULTICENTER STUDY; SKIN NEOPLASMS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CHEMICAL AND DRUG INDUCED LIVER INJURY; DRUG ERUPTIONS; ENDOCRINE SYSTEM DISEASES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; KIDNEY DISEASES; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 84964345287     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.02.025     Document Type: Article

References (50)

1. T. Okazaki, and T. Honjo PD-1 and PD-1 ligands: from discovery to clinical application Int Immunol [Internet] 19 7 2007 Jul 813 824 [cited 2015 Feb 25]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/17606980
2. A. Ribas Tumor immunotherapy directed at PD-1 N Engl J Med [Internet] 366 26 2012 Jun 28 2517 2519 [cited 2015 Aug 21]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/22658126
3. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med [Internet] 363 8 2010 Aug 19 711 723 [cited 2014 Jul 9]; Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3549297&tool=pmcentrez&rendertype=abstract
4. C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, and et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med [Internet] 364 26 2011 Jun 30 2517 2526 [cited 2015 Aug 28]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/21639810
5. C. Robert, J. Schachter, G.V. Long, A. Arance, J.J. Grob, L. Mortier, and et al. Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med [Internet] 372 26 2015 Apr 19 150419053123009. [cited 2015 Apr 21]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/25891173
6. J.S. Weber, S.P. D'Angelo, D. Minor, F.S. Hodi, R. Gutzmer, B. Neyns, and et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Lancet Oncol [Internet] 16 4 2015 Apr 375 384 [cited 2015 Jun 3]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/25795410
7. S.J. O'Day, M. Maio, V. Chiarion-Sileni, T.F. Gajewski, H. Pehamberger, I.N. Bondarenko, and et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study Ann Oncol [Internet] 21 8 2010 Aug 1712 1717 [cited 2015 Sep 14]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/20147741
8. M.A. Postow, J. Chesney, A.C. Pavlick, C. Robert, K. Grossmann, D. McDermott, and et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N Engl J Med [Internet] 372 21 2015 May 21 2006 2017 [cited 2015 Apr 22]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/25891304
9. J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J.J. Grob, C.L. Cowey, C.D. Lao, and et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med [Internet] 373 1 2015 Jul 2 23 34 [cited 2015 Jun 2]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/26027431
10. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med [Internet] 366 26 2012 Jun 28 2443 2454 [cited 2014 Aug 12]; Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3544539&tool=pmcentrez&rendertype=abstract
11. V. Sibaud, I. David, L. Lamant, S. Resseguier, R. Radut, J. Attal, and et al. Acute skin reaction suggestive of pembrolizumab-induced radiosensitization Melanoma Res [Internet] 25 6 2015 Dec 555 558 [cited 2016 Feb 15]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/26312439
12. C. Gaudy, C. Clévy, S. Monestier, N. Dubois, Y. Préau, S. Mallet, and et al. Anti-PD1 Pembrolizumab can induce exceptional fulminant type 1 diabetes Diabetes Care [Internet] 38 11 2015 Nov 26 e182 e183 [cited 2015 Sep 14]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/26310693
13. L. Min, and F.S. Hodi Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis Cancer Immunol Res [Internet] 2 1 2014 Jan 15 18 [cited 2016 Jan 10]; Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4006358&tool=pmcentrez&rendertype=abstract
14. M.A. Postow Managing immune checkpoint-blocking antibody side effects Am Soc Clin Oncol Educ Book [Internet] 35 2015 Jan 76 83 [cited 2015 Jun 2]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/25993145
15. J.S. Weber, J.C. Yang, M.B. Atkins, and M.L. Disis Toxicities of immunotherapy for the practitioner J Clin Oncol [Internet] 33 18 2015 Jun 20 2092 2099 [cited 2015 Oct 9]; Available from: http://jco.ascopubs.org/content/33/18/2092.abstract
16. S.L. Topalian, M. Sznol, D.F. McDermott, H.M. Kluger, R.D. Carvajal, W.H. Sharfman, and et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol [Internet] 32 10 2014 Apr 1 1020 1030 [cited 2015 Mar 16]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/24590637
17. Y. Kato, A. Otsuka, Y. Miyachi, and K. Kabashima Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma J Eur Acad Dermatol Venereol [Internet] 2015 Sep 21 [cited 2015 Nov 16]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/26388113
18. N. Matsumura, M. Ohtsuka, N. Kikuchi, and T. Yamamoto Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma Acta Derm Venereol [Internet] 2015 Aug 13 [cited 2015 Nov 16]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/26270860
19. A. Sahuquillo-Torralba, R. Ballester-Sánchez, C. Pujol-Marco, and R. Botella-Estrada Pembrolizumab: a new drug that can induce exacerbations of psoriasis Actas Dermosifiliogr [Internet] 2015 Nov 3 [cited 2015 Nov 16]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/26546027
20. Opdivo: highlights of prescribing information, http://packageinserts.bms.com/pi/pi-opdivo.pdf [accessed 08.10.15].
21. Keytruda: highlights of prescribing information, http://www.merck.com/product/usa/pi-circulars/k/keytruda/keytruda-pi.pdf [accessed 12.10.15].
22. M. Hecht, L. Zimmer, C. Loquai, C. Weishaupt, R. Gutzmer, B. Schuster, and et al. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients Ann Oncol [Internet] 26 6 2015 Jun 1238 1244 [cited 2016 Jan 25]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/25762352
23. T. Pulvirenti, A. Hong, A. Clements, D. Forstner, A. Suchowersky, A. Guminski, and et al. Acute radiation skin toxicity associated with BRAF inhibitors J Clin Oncol [Internet] 34 3 2016 Jan 20 e17 e20 [cited 2016 Feb 15]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/24868021
24. M.I. Schmidgen, F. Butsch, K. Steinbrink, B. Weidenthaler-Barth, P. Schmücker, A. Jetter, and et al. Lichen planus pemphigoides bei einem 62-jährigen Patienten mit metastasiertem malignen Melanom und kompletter Remission nach Therapie mit Pembrolizumab J Dtsch Dermatol Ges [Internet] 13 2015 (Suppl. S2, pages 20-64):40-1. Available from: http://doi.wiley.com/10.1111/ddg.12784
25. G. Carlos, R. Anforth, S. Chou, A. Clements, and P. Fernandez-Peñas A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab Melanoma Res [Internet] 25 3 2015 Jun 265 268 [cited 2015 Sep 21]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/25831416
26. K. Vigl, F. Weihsengruber, D. Pirkhammer, and K. Rappersberger Generalisierte Blasenbildung unter Pembrolizumab-Therapie J Dtsch Dermatol Ges [Internet] 13 2015 (Suppl. S2, pages 20-64):44-5. Available from: http://doi.wiley.com/10.1111/ddg.12784
27. J.D. Wolchok, B. Neyns, G. Linette, S. Negrier, J. Lutzky, L. Thomas, and et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Lancet Oncol [Internet] 11 2 2010 Feb 155 164 [cited 2015 Sep 21]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/20004617
28. E.B. Garon, N.A. Rizvi, R. Hui, N. Leighl, A.S. Balmanoukian, J.P. Eder, and et al. Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med [Internet] 372 21 2015 May 21 2018 2028 [cited 2015 Apr 24]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/25891174
29. C. Robert, G.V. Long, B. Brady, C. Dutriaux, M. Maio, L. Mortier, and et al. Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med [Internet] 372 4 2015 Jan 22 141116004513004. [cited 2014 Nov 16]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/25399552
30. J. Brahmer, K.L. Reckamp, P. Baas, L. Crinò, W.E.E. Eberhardt, E. Poddubskaya, and et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med [Internet] 373 2 2015 Jul 9 123 135 [cited 2015 Jun 2]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/26028407
31. A. Koop, R. Gutzmer, I. Satzger, and O. Bachmann Autoimmuncolitiden unter der Behandlung mit Checkpoint-Inhibitor - Calprotektin als prädiktiver Marker intestinaler Nebenwirkungen J Dtsch Dermatol Ges [Internet] 13 2015 (Suppl. S2, pages 1-20):3. Available from: http://doi.wiley.com/10.1111/ddg.12783
32. G. Hundorfean, R. Atreya, A. Agaimy, L. Heinzerling, E. Kämpgen, G. Schuler, and et al. Fluorescein-guided confocal laser endomicroscopy for the detection of ipilimumab-induced colitis Endoscopy [Internet] 44 Suppl 2 2012 Jan E78 E79 [cited 2016 Jan 29]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/22396291
33. K.W. Kim, N.H. Ramaiya, K.M. Krajewski, J.P. Jagannathan, S.H. Tirumani, A. Srivastava, and et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings Invest New Drugs [Internet] 31 4 2013 Aug 1071 1077 [cited 2015 Oct 8]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/23408334
34. S.G. Bernardo, M. Moskalenko, M. Pan, S. Shah, H.K. Sidhu, S. Sicular, and et al. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma Melanoma Res [Internet] 23 1 2013 Feb 47 54 [cited 2015 Oct 6]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/23262440
35. O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.-J. Hwu, R. Kefford, and et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med [Internet] 369 2 2013 Jul 11 134 144 [cited 2015 Sep 14]; Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4126516&tool=pmcentrez&rendertype=abstract
36. U. Uslu, A. Agaimy, G. Hundorfean, T. Harrer, G. Schuler, and L. Heinzerling Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with ipilimumab J Immunother [Internet] 38 5 2015 Jun 212 215 [cited 2016 Jan 29]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/25962110
37. A.B. El-Khoueiry, I. Melero, T.S. Crocenzi, T.H. Welling, T.C. Yau, W Yeo, and et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040 J Clin Oncol [Internet] 33 2015 [cited 2015 Oct 8]; Available from: http://meetinglibrary.asco.org/print/1987796
38. Yervoy: summary of product characteristics, http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002213/WC500109299.pdf [accessed 15.10.15].
39. J. Naidoo, D.B. Page, B.T. Li, L.C. Connell, K. Schindler, M.E. Lacouture, and et al. Toxicities of the Anti-PD-1 and Anti-PD-L1 immune checkpoint antibodies Ann Oncol [Internet] 26 12 2015 Dec 2375 2391 [cited 2015 Sep 16]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/26371282
40. S.M. Corsello, A. Barnabei, P. Marchetti, L. De Vecchis, R. Salvatori, and F. Torino Endocrine side effects induced by immune checkpoint inhibitors J Clin Endocrinol Metab [Internet] 98 4 2013 Apr 1361 1375 [cited 2015 Jul 17]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/23471977
41. P.B. Araujo, M.C.A. Coelho, M. Arruda, M.R. Gadelha, and L.V. Neto Ipilimumab-induced hypophysitis: review of the literature J Endocrinol Invest [Internet] 38 11 2015 Nov 1159 1166 [cited 2016 Jan 18]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/25957829
42. C.J. Voskens, S.M. Goldinger, C. Loquai, C. Robert, K.C. Kaehler, C. Berking, and et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network PLoS One [Internet] 8 1 2013 Jan e53745 [cited 2015 Sep 9]; Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3544906&tool=pmcentrez&rendertype=abstract
43. H. Izzedine, V. Gueutin, C. Gharbi, C. Mateus, C. Robert, E. Routier, and et al. Kidney injuries related to ipilimumab Invest New Drugs [Internet] 32 4 2014 Aug 769 773 [cited 2015 Sep 22]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/24687600
44. C. Voskens, A. Cavallaro, M. Erdmann, O. Dippel, E. Kaempgen, G. Schuler, and et al. Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss J Clin Oncol [Internet] 30 33 2012 Nov 20 e356 e357 [cited 2016 Jan 29]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/23045571
45. F. Fadel, K. El Karoui, and B. Knebelmann Anti-CTLA4 antibody-induced lupus nephritis N Engl J Med [Internet] 361 2 2009 Jul 9 211 212 [cited 2015 Sep 22]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/19587352
46. L. Khoja, M.O. Butler, S.P. Kang, S. Ebbinghaus, and A.M. Joshua Pembrolizumab J Immunother cancer [Internet] 3 2015 Jan 36 [cited 2015 Sep 15]; Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4539882&tool=pmcentrez&rendertype=abstract
47. P.M. Forde, K. Rock, G. Wilson, and K.J. O'Byrne Ipilimumab-induced immune-related renal failure-a case report Anticancer Res [Internet] 32 10 2012 Oct 4607 4608 [cited 2015 Oct 12]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/23060594
48. C. Hua, L. Boussemart, C. Mateus, E. Routier, C. Boutros, H. Cazenave, and et al. Association of Vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab JAMA Dermatol [Internet] 152 1 2016 Jan 1 45 51 [cited 2015 Nov 16]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/26501224
49. S.M. Goldinger, P. Stieger, B. Meier, S. Micaletto, E. Contassot, L.E. French, and et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res. (in revision) Clin Cancer Res [Internet] 2016 Mar 8 [cited 2016 Mar 16]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/26957557
50. H. Nishimura, M. Nose, H. Hiai, N. Minato, and T. Honjo Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor Immunity [Internet] 11 2 1999 Aug 141 151 [cited 2016 Feb 22]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/10485649